Manivannan, S., Wales, E. and Zaben, M. ORCID: https://orcid.org/0000-0002-7446-4532 2021. The role of HMGB1 in traumatic brain injury—bridging the gap between the laboratory and clinical studies. Current Neurology and Neuroscience Reports 21 (12) , 75. 10.1007/s11910-021-01158-3 |
Preview |
PDF
- Accepted Post-Print Version
Download (476kB) | Preview |
Abstract
Purpose of Review Traumatic brain injury (TBI) is amongst the leading causes of mortality and morbidity worldwide. However, several pharmacological strategies in the clinical setting remain unsuccessful. Mounting evidence implicates High Mobility Group Box protein 1 (HMGB1) as a unique alternative target following brain injury. Herein, we discuss current understanding of HMGB1 in TBI and obstacles to clinical translation. Recent Findings HMGB1 plays a pivotal role as a ‘master-switch’ of neuro-inflammation following injury and in the regulation of neurogenesis during normal development. Animal models point towards the involvement of HMGB1 signalling in prolonged activation of glial cells and widespread neuronal death. Early experimental studies demonstrate positive effects of HMGB1 antagonism on both immunohistochemical and neuro-behavioural parameters following injury. Raised serum/CSF HMGB1 in humans is associated with poor outcomes post-TBI. Summary HMGB1 is a promising therapeutic target post-TBI. However, further studies elucidating receptor, cell, isoform, and temporal effects are required prior to clinical translation.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
Publisher: | Springer |
ISSN: | 1528-4042 |
Date of First Compliant Deposit: | 28 February 2022 |
Date of Acceptance: | 18 October 2021 |
Last Modified: | 01 Dec 2024 09:30 |
URI: | https://orca.cardiff.ac.uk/id/eprint/147857 |
Citation Data
Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |